Compound overview

BPC-157: What the Evidence Actually Shows

One of the most-searched peptides in the world, sold widely, and supported by almost no human evidence. Here is what is actually known, and what the FDA has said about it.

  • Category 2The FDA list BPC-157 sits on: substances that may present significant safety risks
  • Not approvedIn the United States, for any use, in any form
  • Not a USAN“BPC-157” is a common name, and different substances are sold under it
  • LimitedHow much safety information the FDA says exists for the proposed routes

The short version

BPC-157 is a synthetic peptide marketed for healing and recovery. It is not an approved medicine anywhere in the United States, it is not a dietary supplement, and the products sold online under its name are typically labelled “for research use only” — a label that exists to move a substance outside the rules that would otherwise apply to it.

That is not the same as saying it does nothing. The animal literature is genuinely interesting and reasonably extensive. What is missing is the step between an interesting animal result and a claim about people, and that step is the entire difference between a promising compound and a medicine.

What BPC-157 is

A short synthetic peptide — a chain of amino acids — whose sequence is derived from a protein found in gastric juice. The name stands for Body Protection Compound. It has been studied in laboratory animals since the 1990s, mostly for effects on wound healing, tendon and ligament injury, and gut damage.

It is worth being precise about what “peptide” signals here, because the word is doing a lot of marketing work. Semaglutide is also a peptide, and it is an approved medicine backed by trials in tens of thousands of people. BPC-157 is a peptide with no approval and no completed human efficacy trials. The category tells you about chemistry, not about evidence.

What the FDA has said

BPC-157 appears on the FDA’s Category 2 list — bulk drug substances nominated for use in compounding that the agency has identified as potentially presenting significant safety risks. Being on that list does not mean a substance has been proven dangerous. It means the FDA looked, found reasons for concern, and would consider acting against a compounder using it.

What the FDA says

Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration, and may have complexities regarding peptide-related impurities and characterisation of the active ingredient. The agency has identified no, or only limited, safety-related information for the proposed routes of administration — and therefore lacks sufficient information to know whether the drug would cause harm when administered to humans.

Read that last clause carefully, because it is the honest summary of the entire field. Not “we know it is harmful”. Not “we know it is safe”. We do not have enough information to know. Anyone selling certainty in either direction is going beyond the evidence.

The substance was taken up again at an FDA Pharmacy Compounding Advisory Committee meeting in July 2026, considered for the 503A bulks list. We are tracking that process on our regulatory tracker and will log the outcome when it is published.

The naming problem, which almost nobody mentions

“BPC-157” is a common name, not a United States Adopted Name. There is no single official designation, and the FDA has noted that multiple salts and derivatives are sold commercially under the same common name with inconsistent conventions — free base and acetate forms among them.

Safety

The consequence the FDA identifies is direct: a patient may receive a different bulk substance from the one intended, because two products bearing the same name are not necessarily the same compound.

This is the same class of problem we found with compounded semaglutide, where the FDA reported that some products use salt forms it describes as different active ingredients from the approved drug. In both cases the label names a molecule and nobody has verified that the molecule is what is in the vial. With BPC-157 there is no approved version to compare against at all.

Where the evidence actually stands

  • Animal studies: extensive. Three decades of rodent work reporting effects on tendon, ligament, muscle and gut healing. Consistent enough that the interest in the compound is not manufactured.
  • Human efficacy trials: none published that establish it works. This is the gap that matters. Rodent healing results have a long history of not transferring to people, which is why the approval process exists rather than being a formality.
  • Human safety data: limited, by the FDA’s own assessment. Which means the honest answer to “is it safe” is that nobody knows, not that it is.
  • Product quality: unverified. No regulator checks what is in a research-use-only vial, its purity, or whether the quantity matches the label.

Worth knowing

“No evidence it works” and “evidence it does not work” are different statements. BPC-157 is in the first category. That is a reason for caution, not a verdict.

What this site will not tell you about BPC-157

  • How much to take. There is no approved labeling and no human trial establishing a dose, so every figure in circulation traces back to forums and vendor marketing.
  • How to reconstitute, inject, or administer it.
  • Where to buy it, or which vendors are reputable. We do not review grey-market suppliers.
  • Whether it is right for you. We do not employ clinicians and we have never met you.

Those omissions are deliberate and they are the reason this page exists. The information is easy to find elsewhere; what is hard to find is a straight account of how thin the evidence underneath it is. Our full standards are in the editorial policy.

Sources and method

  • Category 2 listing and the FDA’s stated reasoning. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA. The immunogenicity, impurity and characterisation language is quoted from that page’s entry for BPC-157.
  • The naming problem. Raised in FDA briefing material for the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026, which considered BPC-157 free base and BPC-157 acetate for the 503A bulks list.
  • What we could not verify. We have not read the full advisory committee briefing document or its outcome, and this page does not state one — if the committee has voted, that will be logged on the tracker with its primary source. We have not attempted an exhaustive review of the animal literature; the characterisation above is of its general shape, not a systematic assessment. We have not tested any product.
  • Method. Regulatory statements are quoted from the FDA’s own pages rather than paraphrased from coverage of them. Where we say something is unknown, that reflects an absence we have looked for and not found, not an absence we have assumed.

Regulatory tracker →   Compounded semaglutide →   How we source and verify →

Verified against FDA sources 30 August 2026. We recheck this page whenever the FDA acts on BPC-157.